Influenza virus replication for vaccine development
US11390649B2 · kind B2 · utility
13Cited by
71References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2020 |
| Grant date | Jul 19, 2022 |
| Priority date | — |
| Expiry date | Jul 15, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16152
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at position 711 or the M viral segment encodes a M1 with a residue other than methionine at position 128, wherein the recombinant influenza virus has enhanced replication relative to a corresponding influenza virus having a PB1 viral segment that encodes a PB1 with an isoleucine at position 711 or having a M viral segment that encodes a M1 with methionine at position 128, as well as methods of making and using the virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.